DDW Editor Reece Armstrong speaks to Jasminka Taleska, Director, RLT HCS Readiness and Policy at Novartis, about the opportunities radioligand therapies (RLTs) represent in treating cancer patients.   RA: What are the potentials of RLTs across cancer?  JT: Cancer is an incredibly complex and heterogeneous disease, and, devastatingly, around 10 million people worldwide lose their […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!